Avoiding extra surgery in women with HER2+ or triple-negative breast cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether women with HER2-positive or triple-negative breast cancer who had a complete response to chemotherapy can safely skip radiation or additional surgery. If you had a complete tumor response after chemo and had breast-conserving surgery, you may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You were diagnosed with HER2-positive or triple-negative breast cancer that was small or medium-sized (T1-T2) and had not spread to many lymph nodes (N0-N1).
- You received chemotherapy before surgery (neoadjuvant treatment).
- After chemo and surgery, your tumor was completely gone or almost gone (maximum response or pathologic complete response).
- You had breast-conserving surgery (lumpectomy) and are scheduled for follow-up without more local therapy.
- You do not have a harmful mutation in BRCA1, BRCA2, PALB2, or p53 genes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to see if it is safe to skip surgery for women with triple-negative breast cancer who have no remaining cancer after chemotherapy and immunotherapy. If you qualify, you would avoid surgery but still receive close monitoring to ensure the cancer doesn't come back.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial checks if a breast biopsy can confirm that chemo has destroyed all cancer cells, so you might avoid surgery altogether. It's for people with aggressive breast cancer types who responded well to chemotherapy.
This trial tests whether some women with early-stage, low-risk breast cancer can safely skip lymph node surgery and, in some cases, radiation. It aims to reduce side effects while keeping cancer control the same.
This trial tests whether some women with HER2-positive breast cancer can safely avoid breast surgery if their tumor nearly disappears after chemotherapy. It uses MRI and biopsy results to find people most likely to have no remaining cancer (pCR).
This trial tests whether women who have a complete response to chemotherapy before breast-conserving surgery can safely skip a special radiation boost to the tumor bed. It aims to reduce unnecessary treatment side effects while maintaining good outcomes.
Hear when a new Breast Neoplasm Malignant Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.